UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 21,
2020
SANARA MEDTECH INC.
(Exact name of registrant as specified in its
charter)
|
Texas
|
000-11808
|
59-2219994
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
1200
Summit Avenue, Suite 414
|
Fort
Worth, Texas
|
76102
|
|
(Address
of principal executive offices)
|
(zip
code)
|
Registrant’s telephone number, including area code:
(817)-529-2300
Securities
registered pursuant to Section 12(b) of the Act: None
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item
5.08
Shareholder
Director Nominations.
The
Board of Directors of Sanara MedTech Inc., a Texas corporation (the
“Company”) has established July 9, 2020 as the date of
the Company’s 2020 Annual Meeting of Shareholders (the
“2020 Annual Meeting”) and June 11, 2020 as the record
date for determining shareholders entitled to notice of and to vote
at the 2020 Annual Meeting. Because the Company did not hold an
annual meeting the previous year, shareholders of the Company who
wish to have a proposal considered for inclusion in the
Company’s proxy materials for the 2020 Annual Meeting
pursuant to Rule 14a-8 under the Securities Exchange Act of 1934,
as amended, must ensure that such proposal is received by the
Company’s Corporate Secretary at 1200 Summit Ave., Suite 414,
Fort Worth, Texas 76102, on or before the close of business on June
4, 2020, which the Company has determined to be a reasonable time
before it expects to begin to print and send its proxy materials.
Any such proposal must also meet the requirements set forth in the
rules and regulations of the Securities and Exchange Commission in
order to be eligible for inclusion in the proxy materials for the
2020 Annual Meeting.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
Sanara
MedTech Inc.
|
|
|
|
|
|
|
|
|
Date: May
21, 2020
|
By:
|
/s/ Michael
D. McNeil
|
|
|
|
|
Name: Michael
D. McNeil
|
|
|
|
|
Title: Chief
Financial Officer
|
|